Reduction of SARS-CoV-2 intra-household child-to-parent transmission associated with ventilation: results from a case-control study.
Family
Home environment
Patient isolation
SARS-CoV-2
Ventilation
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
26 06 2023
26 06 2023
Historique:
received:
23
02
2023
accepted:
18
06
2023
medline:
28
6
2023
pubmed:
27
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
Our objective was to describe circumstances of SARS-CoV-2 household transmission and to identify factors associated with a lower risk of transmission in a nationwide case-control study in France. In a descriptive analysis, we analysed cases reporting transmission from someone in the household (source case). Index cases could invite a non-infected household member to participate as a related control. In such situations, we compared the exposures of the index case and related control to the source case by conditional logistic regression matched for household, restricted to households in which the source case was a child, and the index case and related control were the infected child's parents. From October 27, 2020 to May 16, 2022, we included 104 373 cases for the descriptive analysis with a documented infection from another household member. The source case was mostly the index case's child (46.9%) or partner (45.7%). In total, 1026 index cases invited a related control to participate in the study. In the case-control analysis, we included 611 parental pairs of cases and controls exposed to the same infected child. COVID-19 vaccination with 3 + doses versus no vaccination (OR 0.1, 95%CI: 0.04-0.4), isolation from the source case (OR 0.6, 95%CI: 0.4-0.97) and the ventilation of indoor areas (OR 0.6, 95%CI: 0.4-0.9) were associated with lower risk of infection. Household transmission was common during the SARS-CoV-2 pandemic in France. Mitigation strategies, including isolation and ventilation, decreased the risk of secondary transmission within the household. ClinicalTrials.gov registration number: NCT04607941.
Identifiants
pubmed: 37365557
doi: 10.1186/s12889-023-16144-2
pii: 10.1186/s12889-023-16144-2
pmc: PMC10294317
doi:
Substances chimiques
COVID-19 Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT04607941']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1240Informations de copyright
© 2023. The Author(s).
Références
Epidemiologia (Basel). 2021 Dec 27;3(1):1-10
pubmed: 36417263
J Infect Dev Ctries. 2022 Jun 30;16(6):927-936
pubmed: 35797285
Clin Infect Dis. 2021 Aug 2;73(3):e754-e764
pubmed: 33560412
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):212-216
pubmed: 35143470
Ann Epidemiol. 2022 Dec;76:121-127
pubmed: 36210009
JAMA Netw Open. 2022 Apr 1;5(4):e229317
pubmed: 35482308
JAMA. 2022 Apr 26;327(16):1610-1611
pubmed: 35254379
Source Code Biol Med. 2008 Dec 16;3:17
pubmed: 19087314
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Emerg Infect Dis. 2022 Mar;28(3):756-759
pubmed: 35107418
Lancet Reg Health Eur. 2021 Sep;8:100171
pubmed: 34278372
Nat Commun. 2022 Sep 23;13(1):5573
pubmed: 36151099
Biom J. 2018 May;60(3):431-449
pubmed: 29292533
Front Public Health. 2022 Dec 09;10:1087087
pubmed: 36568748
MMWR Morb Mortal Wkly Rep. 2022 Mar 04;71(9):341-346
pubmed: 35238860
Front Pediatr. 2022 Jan 05;9:752993
pubmed: 35071125
JAMA Pediatr. 2022 Jan 1;176(1):59-67
pubmed: 34623377
Nat Commun. 2021 Jun 15;12(1):3643
pubmed: 34131124
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Rev Esp Salud Publica. 2021 Oct 15;95:
pubmed: 34650028
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):779-784
pubmed: 34043610
Lancet Reg Health Eur. 2022 Feb;13:100278
pubmed: 34849500
Lancet Reg Health Eur. 2021 Aug;7:100148
pubmed: 34124709